Published Date : 09 Feb 2023
The global pulmonary drug delivery system market size was exhibited at USD 55.26 billion in 2022 and is projected to hit around USD 92.4 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2030.
In a pulmonary drug delivery system, medication is inhaled via the lungs and enters the bloodstream via the alveolar epithelium. It is an alternative method to subcutaneous and also intravenous injection. It is a non-invasive method. It plays an essential role in the efficiency of pulmonary delivery. For respiratory delivery, many devices are used, such as nebulizers, metered-dose inhalers, and dry powder inhalers. These devices are adapted for use with protein/peptide drugs. In pulmonary drug delivery, patients use an inhaler to inhale their medications. It is used in treating lung diseases, for instance, asthma and chronic obstructive pulmonary disease (COPD). Drug particle properties, breathing patterns, and respiratory tract geometry affect its rate and efficacy. It lowers systemic side effects and increases bioavailability.
Pulmonary drug delivery is used for inhaled beta-agonists, corticosteroids, and anticholinergic agents to treat asthma and COPD. The pulmonary route of administration offers various benefits. The drug is delivered directly to the disease site to treat respiratory diseases. It is provided to perform topical relief. Targeted drug delivery is delivering the drugs to the targeted area. It is a targeted drug delivery system. The drug is infused into the body via the pulmonary route. It is a better drug delivery alternative for treating asthma and chronic obstructive pulmonary disease. It provides quick relief from asthmatic attacks and acute bronchitis.
The increasing air pollution level drives the global pulmonary drug delivery systems market. The surging prevalence of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease, significantly contributes to market growth. The rising investments from private & government organizations for treating pulmonary diseases positively influence market growth. The growing awareness regarding pulmonary health catalyzes market growth. The increasing incidence of chronic obstructive pulmonary diseases and the development of pulmonary drug delivery systems propel the market growth. The escalating awareness of the management & treatment of pulmonary diseases favors market growth.
The increasing number of hospitals & diagnostic centers offers numerous opportunities to expand the global pulmonary drug delivery system market. The presence of key manufacturing companies and the rising government initiatives for treating pulmonary diseases strengthen the market growth. The increasing incidence of respiratory infections and technological advancements favors market growth. The development of novel targeted drug delivery systems fuels the market growth. The rise in the number of initiatives undertaken by government and non-government organizations boosts the overall market growth.
Pulmonary Drug Delivery Systems Market Report Scope
|Market Size in 2023||USD 7 Billion|
|Market Size by 2030||USD 7 Billion|
|Growth Rate From 2022 To 2030||CAGR of 17.2%|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Forecast Period||2022 To 2030|
|Segments Covered||By Product, By Indication, and By Distribution Channel|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
Based on the region, North America dominated the market due to the rising incidence of diseases such as COPD and asthma. The increasing number of patients affected by these diseases and the growing demand for diagnostic devices catalyze the growth of this region. The presence of pharmaceutical and medical device players, inflating disposable income, advanced healthcare infrastructure, geriatric population, and lifestyle changes are expected to drive the growth of the respiratory drug delivery devices market.
Asia Pacific region is expected to witness a promising CAGR due to the surging number of patients suffering from asthmatic and allergic rhinitis and an increasing number of supportive nongovernment organizations. The growing awareness about treating respiratory disorders amongst patients and continuous rising R&D activities by key market players support the growth of the Asia Pacific region.
Market Driver: Increasing prevalence of chronic obstructive pulmonary disease (COPD)
The increasing prevalence of chronic obstructive pulmonary disease (COPD) significantly contributes to global market growth. In line with this, the advantages of the pulmonary drug delivery route positively influence market growth. The product launches and rapid technological advancements create a positive outlook for the market. The marketing strategies adopted by the major players catalyze market growth. The growing adoption of pulmonary drug delivery and the launch of smart and digital inhalers strengthens market growth.
Market Opportunity: Rising Awareness Campaign
The rising awareness campaign to boost the uptake of pulmonary drug delivery devices offers lucrative opportunities for market growth. Government organizations across various countries are taking initiatives to conduct awareness campaigns to spread the importance and benefits of pulmonary drug delivery devices. The development of smart inhalers for asthma and COPD patients favors market growth. Many people are affected by pulmonary diseases, thereby accelerating product demand. The market players are introducing patient-friendly and cost-effective devices. The surging number of hospital admissions due to COPD drives the market growth. The increasing patient awareness regarding the benefits of DPIs and MDIs drives the market during the forecast period.
Market Restraint: Patients’ Unawareness
The unawareness among the population about nasal drug delivery techniques hampers market growth. The patients need to be made aware of the dose administration technique. This restricts the pulmonary drug delivery system market growth. The lack of training, understandability and incorrect usage impede the overall market revenue during the forecast period.
Market Challenge: Regulatory Issues
The stringent government regulations on the approval of pulmonary drug delivery systems challenge market growth. The high pricing pressures hamper the pulmonary drug delivery systems market growth.
Market Key Players:
By Distribution Channel
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1502
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org| +1 9197 992 333